Sterile injectable drug developer and manufacturer for US healthcare
American Regent develops and manufactures brand and generic sterile injectables from US sites in New York, Ohio and Pennsylvania. Its stack pairs plant-floor automation (Allen-Bradley, Siemens PLC, SCADA, HMI) with regulated quality systems (Veeva Vault, LabWare LIMS, Documentum) on legacy AS/400. Hiring skews heavily toward junior manufacturing roles, and job posts repeatedly cite cGMP compliance, inspection readiness and aging CAPAs.
American Regent, Inc. is a Daiichi Sankyo Group company that develops, manufactures and supplies sterile injectable pharmaceuticals. It serves healthcare providers, clinics and hospitals in the United States and Canada, with a portfolio spanning brand and generic specialty injectables. Headquartered in Shirley, New York, the company operates locations in New York, Ohio and Pennsylvania and runs sales territories nationwide. It employs 501–1,000 people, and its activities also cover animal health, clinical research, R&D and contract manufacturing. The company is investing in modernizing and expanding its US manufacturing sites.
American Regent runs AS/400, Veeva Vault, LabWare LIMS, Documentum and PLM, alongside Allen-Bradley and Siemens PLCs, SCADA and HMI on the plant floor, plus HPLC and UPLC lab instruments.
Yes. Manufacturing dominates its US hiring, mostly junior roles, with smaller openings in engineering, operations and quality. Hiring velocity is steady.
American Regent is headquartered in Shirley, New York, with additional locations in Ohio and Pennsylvania and sales territories across the United States.
Other companies in the same industry, closest in size
American Regent, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.